Evidence map›Paper›PMID 40289214›Full record

ArticleScientific reports2025

GRB2 promotes brain metastasis in HER2-positive breast cancer by regulating the Ras/MAPK pathway.

Hongyu Li, Yalin Zhang, Xiao Han, Bingyu Li, Dan Liu, Gang Sun

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Hongyu LiDepartment of Breast Internal Medicine, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, 830011, China. lhygxykdx@163.com.
Yalin ZhangDepartment of Radiation Oncology, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, 830011, China.
Xiao HanDepartment of Radiation Oncology, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, 830011, China.
Bingyu LiDepartment of Breast Internal Medicine, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, 830011, China.
Dan LiuDepartment of Breast Internal Medicine, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, 830011, China.
Gang SunKey Laboratory of Oncology of Xinjiang Uygur Autonomous Region, Department of Breast and Thyroid Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830011, China. sung853219@126.com.

Funding

Natural Science Foundation of Xinjiang 2021D01C41 1The Guiding Funds of Central Government for Supporting the Development of the Local Science and Technology ZYYD2022The Tianchi Talents-Young Doctor Project of Xinjiang Uygur Autonomous Region 2022TCYCLHYTianshan Talents-Leading Talents in Science and Technology Innovation 2023 TSLJ 0038
6 · The paper itself

Abstract

Brain metastasis is emerging as the most serious concern for breast cancer patients. HER2-positive breast cancer is more prone to undergo brain metastasis than other subtypes; notably, there has been little improvement in the treatment of brain metastasis .Our study confirmed the relevance of HER2 status to brain metastasis risk via clinical data analysis and revealed that exerts GRB2 tumorigenic effects by regulating the Ras/MAPK pathway in vivo and in vitro. Both an in situ injection model and a direct cerebral injection model were used to explore the ability of GRB2 to promote the brain metastasis. Results indicated that HER2- positive is a risk factor for brain metastasis according to clinical data. GRB2 enhances proliferation, migration, and invasion while suppressing apoptosis in HER2-positive breast cancer cells in vitro, primarily by regulating phosphorylation and alternative splicing of key proteins within the Ras/MAPK pathway. Notably, tumor cells were able to cross the blood‒brain barrier in both models assessed in this study. Thus, GRB2 is an oncogenic factor that contributes to the malignancy of HER2-positive breast cancer, GRB2 and HER2 can synergistically promote tumor cell penetration of the blood‒brain barrier and induce metastasis.

Indexed as

Brain NeoplasmsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesGRB2 Adaptor ProteinMAP Kinase Signaling Systemras ProteinsAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationFemaleHumansMicePhosphorylationERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGRB2 Adaptor ProteinGRB2 protein, humanras ProteinsBrain metastasisGRB2HER2-positive breast cancerRas/MAPK pathway

Identifiers

PMID40289214
PMCPMC12034778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.